Business
Currency:USD
2023/FY
Stock NameRevenueRatio
TYSABRI1.88B19.08%
SPINRAZA1.74B17.70%
Revenues from anti-CD20 therapeutic programs1.69B17.18%
TECFIDERA1.01B10.29%
Contract manufacturing, royalty and other revenue899.3M9.14%
AVONEX811M8.25%
VUMERITY576.3M5.86%
Other495.3M5.04%
BENEPALI438.8M4.46%
PLEGRIDY294.7M3.00%
View all
Region
Currency:USD
2023/FY
Stock NameRevenueRatio
U.S.5.43B55.24%
Europe2.14B21.75%
Germany868M8.83%
Asia863.4M8.78%
Other531.2M5.40%
